Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sashkia R. Balla"'
Autor:
Ntombi Benede, Marius B. Tincho, Avril Walters, Vennesa Subbiah, Amkele Ngomti, Richard Baguma, Claire Butters, Lina Hahnle, Mathilda Mennen, Sango Skelem, Marguerite Adriaanse, Heidi Facey-Thomas, Christiaan Scott, Jonathan Day, Timothy F. Spracklen, Strauss van Graan, Sashkia R. Balla, Thandeka Moyo-Gwete, Penny L. Moore, Rae MacGinty, Maresa Botha, Lesley Workman, Marina Johnson, David Goldblatt, Heather J. Zar, Ntobeko A.B. Ntusi, Liesl Zühlke, Kate Webb, Catherine Riou, Wendy A. Burgers, Roanne S. Keeton
Publikováno v:
iScience, Vol 27, Iss 1, Pp 108728- (2024)
Summary: SARS-CoV-2 infection in children typically results in asymptomatic or mild disease. There is a paucity of studies on SARS-CoV-2 antiviral immunity in African children. We investigated SARS-CoV-2-specific T cell responses in 71 unvaccinated a
Externí odkaz:
https://doaj.org/article/80c573280346449db3eab66b2620874b
Autor:
Ntombi S. B. Benede, Marius B. Tincho, Avril Walters, Vennesa Subbiah, Amkele Ngomti, Richard Baguma, Claire Butters, Mathilda Mennen, Sango Skelem, Marguerite Adriaanse, Strauss van Graan, Sashkia R. Balla, Thandeka Moyo-Gwete, Penny L. Moore, Maresa Botha, Lesley Workman, Heather J. Zar, Ntobeko A. B. Ntusi, Liesl Zühlke, Kate Webb, Catherine Riou, Wendy A. Burgers, Roanne S. Keeton
Publikováno v:
medRxiv
SUMMARYSARS-CoV-2 infection in children typically results in asymptomatic or mild disease. There is a paucity of studies on antiviral immunity in African children. We investigated SARS-CoV-2-specific T cell responses in 71 unvaccinated asymptomatic S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c775f7940cc6df55684a0b453a3ab4d
https://doi.org/10.1101/2023.05.16.23290059
https://doi.org/10.1101/2023.05.16.23290059
Autor:
Simone I. Richardson, Prudence Kgagudi, Nelia P. Manamela, Haajira Kaldine, Elizabeth M. Venter, Thanusha Pillay, Bronwen E. Lambson, Mieke A. van der Mescht, Tandile Hermanus, Sashkia R. Balla, Zelda de Beer, Talita R. de Villiers, Annie Bodenstein, Gretha van den Berg, Marizane du Pisanie, Wendy A. Burgers, Ntobeko A.B. Ntusi, Fareed Abdullah, Veronica Ueckermann, Theresa M. Rossouw, Michael T. Boswell, Penny L. Moore
Publikováno v:
Cell reports. Medicine.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.4 and BA.5 variants caused major waves of infections. Here, we assess the sensitivity of BA.4 to binding, neutralization, and antibody-dependent cellular cytotoxicity (ADCC)
Autor:
Shabir A. Madhi, Michelle J. Groome, Jayani Pathirana, Sashkia R Balla, Penny L. Moore, Jeffrey R. Dorfman
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 73(4)
Background Although primary maternal cytomegalovirus infections are associated with higher risk of in utero transmission, most fetal infections worldwide result from nonprimary maternal infections. Antibodies directed at glycoprotein B (gB) and the g
Autor:
Catherine Riou, Jinal N Bhiman, Yashica Ganga, Shobna Sawry, Frances Ayres, Richard Baguma, Sashkia R Balla, Ntombi Benede, Mallory Bernstein, Asiphe S Besethi, Sandile Cele, Carol Crowther, Mrinmayee Dhar, Sohair Geyer, Katherine Gill, Alba Grifoni, Tandile Hermanus, Haajira Kaldine, Roanne S Keeton, Prudence Kgagudi, Khadija Khan, Erica Lazarus, Jean Le Roux, Gila Lustig, Mashudu Madzivhandila, Siyabulela F J Magugu, Zanele Makhado, Nelia P Manamela, Qiniso Mkhize, Paballo Mosala, Thopisang P Motlou, Hygon Mutavhatsindi, Nonkululeko B Mzindle, Anusha Nana, Rofhiwa Nesamari, Amkele Ngomti, Anathi A Nkayi, Thandeka P Nkosi, Millicent A Omondi, Ravindre Panchia, Faeezah Patel, Alessandro Sette, Upasna Singh, Strauss van Graan, Elizabeth M Venter, Avril Walters, Thandeka Moyo-Gwete, Simone I Richardson, Nigel Garrett, Helen Rees, Linda-Gail Bekker, Glenda Gray, Wendy A Burgers, Alex Sigal, Penny L Moore, Lee Fairlie
Publikováno v:
PLOS Global Public Health, Vol 4, Iss 4, p e0002703 (2024)
We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.COV2.S, with 91.4% showing evidence of previous SARS-CoV-2 in
Externí odkaz:
https://doaj.org/article/ffaf584224f64bc08915eb129bbe87ff